Novo Nordisk plans to introduce weight loss oral small molecule drugs for 235 million euros
z2z2
发表于 2024-1-25 11:12:21
3290
0
0
On January 23rd, Novo Nordisk announced a cooperation and licensing agreement with EraCal Therapeutics to develop and commercialize EraCal as a weight loss oral small molecule drug.
It is reported that this small molecule drug was discovered by Eracal's zebrafish phenotype screening platform and can target an innovative mechanism of controlling appetite and weight to treat obesity. At present, Novo Nordisk has not disclosed specific information about the project. EraCal is a Swiss biotechnology company based on phenotype drug discovery technology, jointly established by Harvard University and the University of Zurich. In 2022, EraCal reached a research collaboration with Novo Nordisk.
According to the agreement, Novo Nordisk will receive exclusive rights to develop and commercialize the project, while EraCal is eligible for a prepayment of up to 235 million euros, milestone payments for development and commercialization, and royalties after the product is launched and sold.
At the JPM annual meeting held in January, in response to the production capacity challenges faced by the diabetes and obesity sectors, the CEO of Novo Nordisk stated that the company plans to significantly increase production in 2024 and will continue to build production capacity in the coming years. (He Xinyi)
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- ASML's second quarter net sales of 6.24 billion euros are expected to be 6 billion euros
- Deutsche Bank's Q2 sales and trading revenue is estimated to be 2.1 billion euros, with an estimated 2.15 billion euros
- Sanofi's Q2 sales of 10.75 billion euros exceeded expectations
- Vodafone's first quarter service revenue of 7.465 billion euros exceeded estimates
- Novo Nordisk's US stock fell more than 5% before trading
- Holding the 'miracle drug for weight loss', Novo Nordisk generates 133.4 billion DKK in revenue in H1 2024
- Oral "weight loss medication" further advances Novo Nordisk oral semaglutide weight loss phase III research success
- Google loses lawsuit to overturn EU fine of 2.4 billion euros
- Is the dual monopoly situation of Novo Nordisk Lilly in danger? By 2029, there may be 16 GLP-1 weight loss drugs on the market
- Google wins € 1.5 billion advertising antitrust case
-
每经AI快讯,据亿航智能官微消息,公司EH216-S无人驾驶电动垂直起降航空器(eVTOL)获得巴西国家民航局颁发的试验飞行许可证书,并计划在巴西进行测试和试飞。关于EH216-S无人驾驶eVTOL在巴西的认证,中国民航局 ...
- 潇湘才子
- 昨天 08:41
- 支持
- 反对
- 回复
- 收藏
-
今年7月,美国三大海外“债主”所持美国国债齐刷刷缩水,其中日本美债持仓已降至去年10月以来最低。 根据美国财政部当地时间9月18日公布的国际资本流动报告(TIC),2024年7月,美国前三大海外“债主”日本 ...
- 520hacker
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
上证报中国证券网讯(记者俞立严)9月19日,蔚来全新品牌乐道的首款车型——乐道L60正式上市。新车定位家庭智能电动SUV,在采用BaaS电池租用服务后,L60的售价可低至14.99万元,电池租用月费最低为599元。乐道L6 ...
- anhao007
- 前天 11:03
- 支持
- 反对
- 回复
- 收藏
-
每经记者袁园 日前,国务院印发的《关于加强监管防范风险推动保险业高质量发展的若干意见》提出,以新能源汽车商业保险为重点,深化车险综合改革。 “车险综改”从2015年就已经开始逐步推进了,经过 ...
- moshulong
- 前天 21:50
- 支持
- 反对
- 回复
- 收藏